PennyTrader.com Presents Today’s Midday Stock Report: GYST, ONCS, FEEC
The major averages are seeing modest selling in early action as a loss of 0.4% has the Dow pacing the declines.
Shares of Dow component Alcoa (AA 8.63, -0.10) are in focus this morning as the company is set to kick off the second quarter earnings reporting period following today’s closing bell. The Capital IQ Consensus Estimate is calling for earnings per share of $0.06 on revenues of $5.82 billion. Early action is seeing the stock down close to 1.0%.
GYST - Trade Alert
Up 77.78% in morning trading to $.008 with 2M shares traded
The Graystone Company, Inc. is a U.S.-based mining and exploration company focused on acquiring and developing gold and other mineral properties. The Company’s strategy is to build value for shareholders by the identification, acquisition and exploration of early-stage properties that show significant potential for the discovery of gold. The Graystone Company (OTCQB: GYST) announced today that it has reached an agreement with Avenill Ventures, LLC to acquire a working interest in up to 100 oil and gas leases in Kansas.
To Read Full Story go to: http://www.pennytrader.com/
********************
ONCS – News Alert
Up 14% in morning trading to $.285 with 2M shares traded
OncoSec Medical Inc. is a biopharmaceutical company developing advanced-stage OMS ElectroOncology therapies to treat solid tumors and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize the detrimental effects resulting from traditional cancer treatments. OncoSec’s core technology is based upon its proprietary use of an electroporation platform, to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine or a chemotherapeutic agent. Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. OncoSec Medical Inc. (ONCS) announced it has received Investigational Review Board (IRB) approval at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center for a Phase II clinical trial evaluating OncoSec’s OMS ElectroImmunotherapy for the treatment of cutaneous T-cell lymphoma. UCSF investigators are actively recruiting for this clinical trial.
To Read Full Story go to: http://www.pennytrader.com/
********************
FEEC – News Alert
Up 12.08% in morning trading to $.269 with 1M shares traded
Far East Energy Corporation engages in the acquisition, exploration, development, and production of coalbed methane gas properties in the People’s Republic of China. The company holds, through production sharing contracts, interests in three of China’s largest coalbed methane fields: the 485,000 acre Shouyang Block in Shanxi Province; the 573,000 acre Qinnan Block in Shanxi Province; and the 265,000 acre Enhong and Laochang areas in Yunnan Province. Far East Energy Corporation (FEEC) announced today that the Modification Agreement extending the exploration period of its Production Sharing Contract (PSC) for coalbed methane (CBM) in the Shouyang Block in Shanxi Province has received formal approval from the Ministry of Commerce (MofCom) of the People’s Republic of China (PRC).
To Read Full Story go to: http://www.pennytrader.com/
********************
To Follow PennyTrader on Twitter: http://twitter.com/pennytrader
To Join Our Facebook Page: http://www.facebook.com/PennyTrader2
PennyTrader.com, PO Box 791, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@PennyTrader.com.This email address is being protected from spam bots, you need Javascript enabled to view it
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on PennyTrader.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
Leave a Comment